/Passle/596df0e43d947619ec025f26/SearchServiceImages/2021-06-20-22-57-41-873-60cfc7e5e5416a028865e9f7.jpg)
Summary In a significant victory for pharmaceutical patentees, the Federal Court in Ono Pharmaceutical Co. Ltd v Commissioner of Patents...
This browser is not actively supported anymore. For the best passle experience, we strongly recommend you upgrade your browser.
Add a bookmark to get started
Global Site
Back
Cortex - Life Sciences Insights
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2021-06-09-12-08-24-242-60c0af38fac91e08f49c118f.jpg)
The Portuguese Parliament will meet to debate two draft-laws aimed at legalizing cannabis for non-medical personal use. Both draft-laws...
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/5ed622ef8cb62a041c7fddf8/2021-06-03-10-15-34-987-60b8abc6400fb30bd8bd773d.jpg)
Back in April 2017, The Times ran a story detailing how a drug giant had a “secret plan” to destroy a cancer medicine unless large price...
DLA Piper is a global law firm operating through various separate and distinct legal entities. For further information about these entities and DLA Piper's structure, please refer to the Legal Notices page of this website. All rights reserved. Attorney advertising.
© 2023 DLA Piper
Email Disclaimer
Unsolicited e-mails and information sent to DLA Piper or the independent DLA Piper Relationship firms will not be considered confidential, may be disclosed to others, may not receive a response, and do not create a lawyer-client relationship with DLA Piper or any of the DLA Piper Relationship firms. Please do not include any confidential information in this message. Also, please note that our lawyers do not seek to practice law in any jurisdiction in which they are not properly permitted to do so.
